Boothbay Fund Management LLC Sells 32,424 Shares of Cellebrite DI Ltd. (NASDAQ:CLBT)

Boothbay Fund Management LLC lowered its position in Cellebrite DI Ltd. (NASDAQ:CLBT - Free Report) by 38.9% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 50,978 shares of the company's stock after selling 32,424 shares during the quarter. Boothbay Fund Management LLC's holdings in Cellebrite DI were worth $1,123,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently bought and sold shares of the business. NewEdge Advisors LLC grew its stake in Cellebrite DI by 600.7% in the fourth quarter. NewEdge Advisors LLC now owns 3,910 shares of the company's stock worth $86,000 after purchasing an additional 3,352 shares in the last quarter. R Squared Ltd bought a new position in Cellebrite DI in the 4th quarter worth approximately $100,000. Polen Capital Management LLC bought a new stake in shares of Cellebrite DI during the fourth quarter valued at about $222,000. Victory Capital Management Inc. acquired a new stake in shares of Cellebrite DI in the 4th quarter worth approximately $234,000. Finally, HighTower Advisors LLC acquired a new stake in Cellebrite DI in the fourth quarter worth approximately $274,000. 45.88% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of research firms recently commented on CLBT. Lake Street Capital boosted their target price on shares of Cellebrite DI from $17.00 to $26.00 and gave the stock a "buy" rating in a report on Friday, February 14th. Needham & Company LLC reissued a "buy" rating and issued a $28.00 price objective on shares of Cellebrite DI in a research note on Wednesday, April 2nd. Finally, JPMorgan Chase & Co. boosted their price objective on shares of Cellebrite DI from $24.00 to $28.00 and gave the stock an "overweight" rating in a research note on Tuesday, February 11th. Seven analysts have rated the stock with a buy rating, Based on data from MarketBeat, Cellebrite DI presently has an average rating of "Buy" and an average target price of $23.43.

Cellebrite DI Price Performance

CLBT stock traded up $0.28 on Friday, reaching $20.14. 762,064 shares of the company were exchanged, compared to its average volume of 1,421,025. The firm has a market capitalization of $4.82 billion, a PE ratio of -14.49, a PEG ratio of 4.27 and a beta of 1.44. Cellebrite DI Ltd. has a 12 month low of $10.25 and a 12 month high of $26.30. The stock's fifty day moving average price is $18.82 and its 200 day moving average price is $20.20.

Cellebrite DI (NASDAQ:CLBT - Get Free Report) last announced its quarterly earnings data on Thursday, February 13th. The company reported $0.07 EPS for the quarter, missing analysts' consensus estimates of $0.10 by ($0.03). Cellebrite DI had a negative net margin of 70.54% and a positive return on equity of 58.70%. As a group, research analysts expect that Cellebrite DI Ltd. will post 0.3 EPS for the current fiscal year.

Cellebrite DI Company Profile

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.